AI Article Synopsis
- This study explored how the COVID-19 pandemic affected the management of non-small cell lung cancer (NSCLC) patients in Italy, utilizing a survey sent to 95 thoracic oncologists.
- Findings revealed that most oncologists (77%) reported significant changes in outpatient management, resulting in delayed diagnoses and fewer patients enrolled in clinical trials.
- Telemedicine was highlighted as an effective tool for patient care, while treatment adherence to established guidelines remained, with notable adjustments in second-line treatments and care for elderly patients.
Article Abstract
This study investigated the clinical management of non small cell lung cancer (NSCLC) patients during the first wave of coronavirus disease 2019 (COVID-19) outbreak in Italy. A 29-questions survey was sent to 95 Italian thoracic oncologists, with 77 % of them declaring significant changes in the outpatients management and treatment. The results of this survey pointed out a significant delay of lung cancer diagnosis along with a relevant reduction of patients' accrual within clinical trials. Telemedicine emerged as a valid support for patient-healthcare interactions. Therapeutic indications followed the guidelines for adjuvant chemotherapy and concurrent chemo-radiation. Clinical indications to first-line therapies were largely confirmed, while major changes regarded the selection of second line treatment options as well as the management of elderly population. This work may represent a valid source of information to improve the clinical management of NSCLC patients during second wave of COVID-19 pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691849 | PMC |
| http://dx.doi.org/10.1016/j.critrevonc.2020.103189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!